Deerfield Capital

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Itamar Medical is a publicly traded medical device company based in Israel’s Caesarea Industrial Park that develops non-invasive medical devices using the proprietary PAT (Peripheral Arterial Tone) signal. Since its founding in 1997, the Company has engaged in research and development of non-invasive medical devices for diagnosis of various medical conditions, including cardiovascular disease and respiratory disorders. The first two product lines from Itamar Medical, based on unique technology developed by the Company, are the WatchPAT™ home appliance for respiratory sleep disorder diagnosis, and EndoPAT™, the only device approved by the FDA for testing endothelial (arterial) function and assessing the risk of coronary artery disease and other cardiovascular diseases.

PQ Bypass is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions. PQ Bypass is a former Company-In-Residence at the Fogarty Institute for Innovation and is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker and also have extensive experience developing medical devices for venture-backed startups such as Evalve, AccessClosure, Altura, and DVI.

Stelexis Therapeutics is to become the cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms. The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.

Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential.

Quartet is a platform that makes it easier for people to get the best mental health care for them. The best care should fit their preferences and clinical needs, take their insurance, and link to the rest of their healthcare experience. Quartet was founded in 2014 and is based in New York, United States.

Chondrial Therapeutics s a clinical-stage biotechnology company focused on the treatment of rare diseases. It is dedicated to the pursuit of scientific research leading to the treatment for Friedreich’s Ataxia and other mitochondrial diseases.

Vensun Pharmaceuticals is a pharmaceutical company developing generic prescription products in various dosage forms. As a rapidly emerging generic pharmaceutical company, Vensun has filed several Abbreviated New Drug Applications (ANDAs) with the FDA through its partnerships and currently has over 30 products in active development. We are actively seeking additional opportunities for partnerships, strategic alliances, and product acquisitions to enhance our existing development portfolio.

Alphatec Spine is a medical device company that designs, develops, and manufactures products for the surgical treatment of spine disorders, with a focus on treating conditions affecting the aging spine. It offers thoracolumbar products, such as pedicle screw-based semi-rigid rods designed to be part of an adjunct to fusion construct, as well as posterior thoracolumbar access, spinal fixation, anterior lumbar plating, pedicle screw, and lumbar fixation systems; cervicothoracic products, including occipital fixation systems, posterior cervicothoracic fixation systems with adjustable bridges, and anterior cervical plating systems; and interbody products, such as cervical interbody and vertebral body replacement systems, as well as anterior, posterior, and transforaminal lumbar interbody fusion systems. The company also provides biologics, including demineralized bone matrix and scaffolds, biologic and structural allograft products, cervical allograft systems, and amniotic tissue barriers; minimally invasive (MIS) solutions, such as MIS posterior fixation systems and spinous process fixation systems; spinal fracture reduction and fixation systems, and interspinous spacer systems for aging spines; and spinal fracture reduction systems. It offers its products in the United States. The company also markets its products through a direct sales force in France, Italy, and the United Kingdom; independent distributors in the rest of Europe, the Middle East and Africa, South America, and Latin America; subsidiaries in Asia and Australia; distributors in China, Korea, and Australia; and an affiliate internationally. Alphatec Spine, Inc. was formerly known as Alphatec Manufacturing, Inc. The company was founded in 1990 and is headquartered in Carlsbad, California. It has locations in Tokyo, Japan; Kowloon, Hong Kong; Voisins le Bretonneux and Beaurains, France; Oxford, United Kingdom; and Engen, Germany. Alphatec Spine, Inc. operates as a subsidiary of Alphatec Holdings, Inc.

Foundation Medicine plans to create clinical diagnostic tests that can use the latest in genetic sequencing technology to identify personalized cancer therapies for patients.

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.